Why women are hit harder by lung disease: biology, hormones, and risk factors
Latest news on WhatsApp أجدد الأخبار على واتساب
A growing body of research suggests women may carry a higher burden in several lung conditions compared with men. The gap is not only shaped by exposure patterns—such as smoking, indoor and outdoor air pollution, or workplace irritants—but also by biological and hormonal differences that can influence how the lungs are affected and how the body responds to inflammation and treatment. The pattern appears in common diseases such as asthma and chronic obstructive pulmonary disease (COPD), and in rarer conditions such as pulmonary arterial hypertension (PAH).
One leading explanation center on differences in respiratory anatomy. Imaging-based studies have indicated that women, on average, may have smaller airways and distinct airway structures compared with men. That can mean airway narrowing or inflammation may translate into symptoms more quickly or more intensely in some women—particularly with exposure to tobacco smoke or other airway irritants.
In asthma, the sex gap shifts across the lifespan. After puberty, many studies report higher prevalence and often greater severity among women. Researchers link part of this difference to hormonal and immune influences, as sex hormones may affect airway inflammation and hyper-responsiveness across life stages such as the menstrual cycle, pregnancy, and menopause.
For COPD, research has examined whether some women may develop significant symptoms with lower cumulative smoking exposure, and whether the disease profile differs—for example, a stronger small-airway component in some cohorts. A study published in 2025 reported higher COPD risk in women than in men, while emphasizing that the reasons are likely multifactorial rather than explained by a single factor such as “greater sensitivity to smoking.”
In Canada, lung cancer remains central to women’s lung health. Estimates from the Canadian Cancer Society project lung cancer as the leading cause of cancer death in women (as in men), and suggest roughly 1 in 16 women will develop lung and bronchus cancer in their lifetime. Canadian advocacy and research groups have also pointed to an increasing share of the burden among women in recent projections—reinforcing the need for prevention, earlier detection, and risk-focused follow-up.
The gap is not limited to common diseases. PAH shows a clear female predominance across major registries, although the exact female-to-male ratio varies between studies.
From a practical standpoint, a significant portion of risk can be reduced through a few high-impact steps: avoiding smoking and secondhand smoke, testing homes for radon (particularly relevant in Canada), and not dismissing persistent symptoms such as ongoing shortness of breath, recurrent wheeze, or a cough that does not resolve. Early assessment—such as spirometry—can help clarify asthma or COPD, and people at higher risk of lung cancer may want to ask about screening options available in their province.
